Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Half Yearly Report

28 Aug 2013 09:40

RNS Number : 6194M
Oxford Advanced Surfaces Group PLC
28 August 2013
 



OXFORD ADVANCED SURFACES GROUP PLC

(AIM: OXA)

 

Half Year results for the period ended 30 June 2013 and strategic update

 

Oxford Advanced Surfaces Group ("OAS") the AIM listed technology developer targeting engineered materials and surface modification applications in the automotive, aerospace, communications and renewable energy markets announces its half year results for the period ended 30 June 2013 and also an update to strategic direction.

 

Highlights:

 

· Group has continued to make good technical and commercial progress.

· Costs remain tightly controlled despite an increase in development activity. The half year loss before tax stands at £932,000.

· The Group retains a strong balance sheet with cash balances of £3.46m at 30 June 2013.

· A number of applications utilising OntoTM are currently being developed with a number of global corporations who are leaders in the adhesion, renewable energy, automotive and aerospace sectors.

· Following a strategic review, further investment in the VISARCTM antireflection coating technology is to be suspended due to market and competitive changes. Additional resource will be focussed on our highly differentiated and proprietary OntoTM technology platform, for which we believe there is significant market potential.

· Targeted annual cost savings of £0.8m by 2014 driven by headcount reduction, merging of development groups and reduction in support costs.

· Investigation of adjacent and synergistic technologies aimed at strengthening the OAS technology portfolio, including additional uses of our MPS nanoparticles.

 

 

Adrian Meldrum, CEO said:

 

"During the first half of 2013 we have seen strong interest in our OntoTM technology across a number of targeted global industries and progress is promising. Our OntoTM strategy and development plans will continue with our primary focus on adhesion promotion applications within our targeted markets.

 

The decision to suspend development on our VISARCTM technology platform will enable us to increase investment in our proprietary OntoTM technology where we believe there is strong market potential. This growth opportunity is being driven by an increased use of plastics and polymers, with surface functionalisation and adhesion requirements, in automotive, aerospace, communications and renewable energy markets.

 

We believe these changes will strengthen OAS's position and accelerate delivery in our development and customer engagement plans in areas where we hold differentiating and enabling technology."

 

28 August 2013

 

Enquiries:

 

Oxford Advances Surfaces Group Plc

www.oxfordsurfaces.com

 

Adrian Meldrum, Chief Executive Officer

Philip Spinks, Chief Financial Officer T: 01865 854 807

 

W H Ireland Limited

www.wh-ireland.co.uk

 

John Wakefield T: 0117 945 3471

 

REVIEW OF THE CHAIRMAN AND THE CHIEF EXECUTIVE OFFICER

 

The Group has continued to make good technical and commercial progress in the six months to 30 June 2013 in addition to keeping a tight control on our cash spend. Our balance sheet remains strong and we have £3.46m to support our continued development and commercialisation.

 

During the period we took the positive results of our work on OntoTM to a number of companies operating in our identified target markets where the unique adhesion promotion offered by OntoTM has the potential to yield major benefits to end users. We are now testing OntoTM variants with global market leaders in the automotive, aerospace, communications and renewable energy sectors. We anticipate that these development programmes will move towards commercialisation this year.

 

Following a strategic review by the Board in August, we have decided to increase our focus on commercialisation of our OntoTM technology and to suspend further VISARCTM investment at the present time. This reflects a strong belief in our proprietary OntoTM technology and a need to focus our resources in differentiated technology areas.

 

Strategic Review

The strategic review and resultant repositioning provides OAS with a long term business proposition based on a clearly differentiated and disruptive technology offering, together with a reduced cash burn and strong cash position.

The strategic decisions made as part of this review are as follows:

· Increased investment in our proprietary OntoTM technology development platform for adhesion promotion and other surface functionalisation applications

· Suspension of investment in the development of the VISARCTM antireflection coating offering

· Significant reduction in annual development spend with targeted costs savings of £0.8m driven by headcount reduction, simplification of the business structure, merging of development groups and reduction in support function costs

· Investigation of adjacent and synergistic technology offerings aimed at strengthening the OAS technology portfolio, including our MPS nanoparticle offering

We believe these changes will result in OAS being in a strong position to accelerate and deliver on our development and customer engagement plans in areas where we hold differentiating and enabling technology.

The individual technology offerings along with the rationale for the changes are detailed below.

OntoTM Technology Offering

Our OntoTM strategy and development plans are primarily focussed on adhesion promotion and surface modification applications. We are seeing increasing market demand for new and novel lightweight polymer materials and associated adhesion promoters, driven by energy efficiency and regulatory changes in automotive, aerospace, communications and renewable energy. OAS's key intellectual property in this area is an important strategic factor supporting development.

A number of key customer programmes are progressing well across multiple applications and we aim to develop these to commercialisation in late 2013. Short term technical milestones will need to be met to allow this to happen, along with further customer developments as we strengthen the focus on our OntoTM technology platform.

VISARCTM Technology Offering

Following the decision to suspend development on our VISARCTM technology platform, the basis of which is a mesoporous silica (MPS) nanoparticle, we will undertake a full evaluation of how best to generate value from our particle manufacture know-how and the intellectual property portfolio we have established for this technology.

In addition we believe that our nanoparticle IP and know-how also offers significant value in non-ARC applications which we will endeavour to exploit.

Outlook

The OAS board and management team believe that the strategic review, repositioning and associated changes put OAS in the best position to drive forward with development and customer engagement plans in order to maximise shareholder value. Increased focus on differentiated and proprietary technology offerings will drive our ability to succeed. Strong market pull and emerging applications will provide significant commercial opportunities for the company when combined with focussed internal technology execution.

We would like to take this opportunity to thank our shareholders for their continued support and patience. We would also like to thank our committed staff who continue to work tirelessly to progress our technology to commercial success.

 

 

Adrian Meldrum

Chief Executive Officer

 

 

Dr Peter Rowley

Non-executive Chairman

 

28 August 2013

Company Number: 5845469

 

INTERIM CONSOLIDATED INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME

Unaudited interim condensed consolidated financial statements to 30 June 2013

 

Six months to

30 June 2013

Six months to

30 June 2012

Year to

31 December 2012

Unaudited

Unaudited

Audited

£'000

£'000

£'000

CONTINUING OPERATIONS

Revenue

3

69

86

Cost of sales

(90)

(89)

(169)

GROSS PROFIT

(87)

(20)

(83)

Research and development costs

(412)

(474)

(909)

Other administrative costs

(417)

(380)

(803)

Share based payments

(60)

(1)

(27)

Total administrative costs

(889)

(855)

(1,739)

LOSS FROM OPERATIONS

(976)

(875)

(1,822)

Finance income

44

67

126

LOSS BEFORE TAX

(932)

(808)

(1,696)

Income tax credit

75

68

159

LOSS FOR THE YEAR AND TOTAL COMPREHENSIVE LOSS FOR THE YEAR

(857)

(740)

(1,537)

Loss per share attributable to the equity holders of the company:

Total and continuing:

- Basic and diluted (pence)

(0.44)

(0.38)

(0.79)

 

There were no items of other comprehensive income for the periods covered by these statements and therefore the loss for the year is also the total comprehensive loss for the year net of tax.

 

 

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION

Unaudited interim condensed consolidated financial statements to 30 June 2013

 

 

30 June 2013

30 June 2012

31 December 2012

Unaudited

Unaudited

Audited

£'000

£'000

£'000

ASSETS

NON-CURRENT ASSETS

Intangible assets

428

346

396

Plant and equipment

178

227

191

606

573

587

CURRENT ASSETS

Stocks

-

9

-

Trade and other receivables

327

420

295

Short-term investments and cash and cash equivalents

3,464

4,993

4,304

3,791

5,422

4,599

LIABILITIES

CURRENT LIABILITIES

Trade and other payables

153

185

145

NET CURRENT ASSETS

3,638

5,237

4,454

LIABILITIES

NON-CURRENT LIABILITIES

Provisions

10

10

10

NET ASSETS

4,234

5,800

5,031

SHAREHOLDERS EQUITY

Called up share capital

1,977

1,957

1,977

Share premium

10,603

10,423

10,603

Merger reserve

6,369

6,369

6,369

Reverse acquisition reserve

(6,831)

(6,831)

(6,831)

Retained earnings

(8,214)

(7,017)

(7,365)

Share based payments reserve

330

899

278

TOTAL EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY

4,234

5,800

5,031

 

 

INTERIM CONSOLIDATED CASH FLOW STATEMENT

Unaudited interim condensed consolidated financial statements to 30 June 2013

 

 

Six months to 30 June 2013

Six months to 30 June 2012

Year to 31 December 2012

Unaudited

Unaudited

Audited

£'000s

£'000s

£'000s

Loss before tax

(932)

(808)

(1,696)

Depreciation and amortisation charges

64

72

141

(Profit)/Loss on disposal of property, plant and equipment

(1)

1

1

Share based payment expense

60

1

27

Finance income

(44)

(67)

(126)

(853)

(801)

(1,653)

(Increase)/Decrease in stocks

-

(8)

1

(Increase)/Decrease in trade and other receivables

(24)

(15)

29

Increase in trade and other payables

8

8

(32)

Cash outflow from operations

(869)

(816)

(1,655)

Income tax received

49

-

145

Net cash outflow from operating activities

(820)

(816)

(1,510)

Cash flows from investing activities

Purchase of intangible assets

(48)

(20)

(84)

Purchase of property, plant and equipment

(35)

(40)

(59)

Decrease in cash placed on long-term deposit

1,680

735

1,570

Interest received

63

64

150

Net cash inflow from investing activities

1,660

739

1,577

Net cash from financing activities

Share issue

-

-

2

Net cash inflow from financing activities

-

-

2

Increase/(Decrease) in cash and cash equivalents

840

(77)

69

Cash and cash equivalents at beginning of year

624

555

555

 

Cash and cash equivalents at end of year

1,464

478

624

Short term investments

2,000

4,515

3,680

Short-term investments and cash and cash equivalents

3,464

4,993

4,304

 

Under IAS 7 cash held on long-term deposits that cannot readily be converted into cash has been classified as short term investments. These investments range between three and 12 months.

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

A copy of these interim condensed consolidated financial statements will be available on the Group's website www.oxfordsurfaces.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR MMGZRNRLGFZG
Date   Source Headline
22nd Mar 201910:39 amRNSHolding(s) in Company
20th Mar 20197:00 amRNSDirectors' Shareholdings
19th Mar 20194:52 pmRNSReplacement - Total Voting Rights and Notice of...
19th Mar 20193:35 pmRNSHolding(s) in Company
19th Mar 20193:32 pmRNSHolding(s) in Company
15th Mar 20198:10 amRNSTotal Voting Rights and Notice of Results
12th Mar 20197:00 amRNSGrant of Options
11th Mar 201912:58 pmRNSResult of Meeting & Directorate Change
7th Mar 20199:00 amRNSIssue of Equity
25th Feb 20197:00 amRNSAcquisition, Placing & Waiver of Rule 9
14th Feb 20193:58 pmRNSHolding(s) in Company
6th Feb 20194:42 pmRNSHolding(s) in Company
6th Feb 20194:41 pmRNSHolding(s) in Company
17th Jan 20197:00 amRNSDisposal of SICM business
20th Dec 20187:00 amRNSUpdate, Conditional Acquisition & Proposed Placing
30th Nov 20187:00 amRNSPublication of Paper in leading Journal
6th Sep 20183:06 pmRNSExercise of Options and Issue of Equity
6th Sep 20187:00 amRNSInterim Results
15th Aug 20187:00 amRNSFurther Pioneer Agreements and Notice of Results
19th Jul 20187:00 amRNSPublication of Scientific Paper
11th Jun 20187:00 amRNSDirectorate Changes
11th Jun 20187:00 amRNSIssue of Equity
16th May 201811:45 amRNSResult of AGM, name change and new website
24th Apr 20187:00 amRNSDirector Dealing
19th Apr 20187:00 amRNSSecond Pioneer Agreement Signed
12th Apr 20187:00 amRNSFirst Pioneer Agreement Signed
5th Apr 20183:28 pmRNSDirector Dealing
28th Mar 20187:00 amRNSFinal results for the year ended 31 December 2017
6th Feb 20187:00 amRNSMoUs signed with pioneers
19th Jan 20189:00 amRNSPublication of Scientific Paper
17th Jan 20187:00 amRNSPublication of Scientific Paper
6th Dec 20177:00 amRNSDirector Dealing
4th Dec 20177:00 amRNSNew Share Option Scheme and Grant to PDMR
1st Dec 20171:01 pmRNSDirectors' Dealing
28th Nov 20179:47 amRNSDirector Dealing
22nd Nov 20175:50 pmRNSHolding(s) in Company
20th Nov 201711:02 amRNSHolding(s) in Company
8th Nov 20178:11 amRNSCompletion of Acquisition, Appointment of Director
3rd Nov 20177:00 amRNSAcquisition of OpenIOLabs Limited
4th Oct 20177:00 amRNSChange of Adviser
12th Sep 20177:00 amRNSHalf-year Report
19th May 201711:34 amRNSResult of AGM
26th Apr 20177:00 amRNSDirectorate Changes
28th Mar 20177:00 amRNSFinal Results
16th Feb 20177:00 amRNSDigital Chemistry to be performed in space
31st Jan 20178:03 amRNSAdvisory Committee
31st Jan 20177:00 amRNSPresentation at Healthcare Conference
9th Jan 20177:00 amRNSDigitalGlasswareT
15th Sep 20167:00 amRNSHalf-year Report
12th May 201611:45 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.